Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 15/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 18/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 17/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 16/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 16/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 14/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 14/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 14/20 | 0.61 |
| ▸ | HDAC9 | Q9UKV0 | 14/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 14/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 13/20 | 0.61 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | BRD4 | O60885 | 1/20 | 0.60 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.60 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | LTA4H | P09960 | 1/20 | 0.60 |
| ▸ | NR0B1 | P51843 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30345341 | 0.85 | HDAC2 (0.47) | HDAC2HDAC8HDAC6HDAC1HDAC3 | |
| SCHEMBL27770767 | 0.84 | HDAC2 (0.80) | HDAC2HDAC8HDAC6HDAC1HDAC3 | |
| SCHEMBL20487166 | 0.84 | HDAC4 (0.66) | HDAC2HDAC8HDAC6HDAC1HDAC3 | |
| SCHEMBL1065527 | 0.82 | HDAC6 (0.74) | HDAC2HDAC8HDAC6HDAC1HDAC3 | |
| SCHEMBL1433994 | 0.82 | HDAC6 (0.74) | HDAC2HDAC8HDAC6HDAC1HDAC3 | |
| SCHEMBL28784814 | 0.82 | HDAC2 (0.77) | HDAC2HDAC8HDAC6HDAC1HDAC3 | |
| Hydroxyamine SCHEMBL1268824 | 0.82 | HDAC6 (0.79) | HDAC2HDAC8HDAC6HDAC1HDAC3 | |
| SCHEMBL6669511 | 0.82 | HDAC4 (0.85) | HDAC2HDAC8HDAC6HDAC1HDAC3 | |
| SCHEMBL137348 | 0.82 | HDAC4 (0.85) | HDAC2HDAC8HDAC6HDAC1HDAC3 | |
| SCHEMBL1065393 | 0.82 | HDAC4 (0.85) | HDAC2HDAC8HDAC6HDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190374525-A1 | TREATMENT OF DIABETES AND ASSOCIATED METABOLIC CONDITIONS WITH EPIGENETIC MODULATORS | TEMPLE OTORONGO LLC (US) | 2019-12-12 | — | — | US | claimed |
| US-20240173320-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | Epizyme, Inc. | 2024-05-30 | — | — | US | disclosed |
| US-20240100079-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS IN THE INNER EAR OF ADULT MAMMALS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-03-28 | — | — | US | disclosed |
| US-11466252-B2 | Expansion and differentiation of inner ear supporting cells and methods of use thereof | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | Frequency Therapeutics, Inc. | 2022-06-23 | — | — | US | disclosed |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | Epizyme, Inc. | 2021-07-15 | — | — | US | disclosed |
| WO-2020018848-A1 | METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING AMIDO COMPOUNDS | IDEAYA BIOSCIENCES, INC. (US) | 2020-01-23 | — | — | WO | disclosed |
| US-20190374525-A1 | TREATMENT OF DIABETES AND ASSOCIATED METABOLIC CONDITIONS WITH EPIGENETIC MODULATORS | TEMPLE OTORONGO LLC (US) | 2019-12-12 | — | — | US | disclosed |
| US-20190010449-A1 | Expansion and Differentiation of Inner Ear Supporting Cells and Methods of Use Thereof | MASSACHUSETTS EYE AND EAR INFIRMARY | 2019-01-10 | — | — | US | disclosed |
| WO-2018226939-A1 | COMPOSITIONS AND METHODS OF TREATING AND/OR PREVENTING CANCER | RANEDIS PHARMACEUTICALS, LLC (US) | 2018-12-13 | — | — | WO | disclosed |
| EP-3191104-A1 | METHODS FOR TREATING A DISEASE OR DISORDER USING ORAL FORMULATIONS OF CYTIDINE ANALOGS IN COMBINATION WITH AN ANTI-PD1 OR ANTI-PDL1 MONOCLONAL ANTIBODY | Celgene Corporation (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016040238-A1 | METHODS FOR TREATING A DISEASE OR DISORDER USING ORAL FORMULATIONS OF CYTIDINE ANALOGS IN COMBINATION WITH AN ANTI-PD1 OR ANTI-PDL1 MONOCLONAL ANTIBODY | CELGENE CORPORATION (US) | 2016-03-17 | — | — | WO | disclosed |
| WO-2015195634-A1 | METHODS FOR TREATING EPSTEIN-BARR VIRUS (EBV) ASSOCIATED CANCERS USING ORAL FORMULATIONS OF 5-AZACYTIDINE | CELGNE CORPORATION (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2014160698-A1 | SOLID FORMS COMPRISING 4-AMINO-I-β-D-RIBOFURANOSYL-1,3,5-TRIAZIN-2(1H)-ONE AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF | CELGENE CORPORATION (US) | 2014-10-02 | — | — | WO | disclosed |
| EP-2405908-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING RDEA119/BAY 869766 FOR THE TREATMENT OF SPECIFIC CANCERS | Ardea Biosciences, Inc. (US) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010105110-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING RDEA119/BAY 869766 FOR THE TREATMENT OF SPECIFIC CANCERS | ARDEA BIOSCIENCES, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| EP-1541549-A1 | Tricyclic hydroxamate and benzaminde derivatives, compositions and methods | Exonhit Therapeutics S.A. (FR) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173320-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | EHMT2, BHMT2, BHMT | HDAC2 268/4885HDAC8 454/4885HDAC6 821/4885 |
| US-20190374525-A1 | TREATMENT OF DIABETES AND ASSOCIATED METABOLIC CONDITIONS WITH EPIGENETIC MODULATORS | GPR119, SREBF1, SREBF2 | HDAC2 23/4885HDAC8 37/4885HDAC6 386/4885 |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | OTC, EXOSC5, ENTPD5 | HDAC2 2986/4885HDAC8 3334/4885HDAC6 1191/4885 |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | EHMT2, BHMT2, BHMT | HDAC2 268/4885HDAC8 454/4885HDAC6 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.